UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 28,276 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 9.9% during the 3rd quarter, HoldingsChannel reports. The firm owned 258,661 shares of the company’s stock after selling 28,276 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Hims & Hers Health were worth $4,765,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in HIMS. Nisa Investment Advisors LLC increased its stake in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after acquiring an additional 1,603 shares during the last quarter. Quest Partners LLC increased its stake in Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after acquiring an additional 3,507 shares during the last quarter. CWM LLC increased its stake in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares during the last quarter. Van ECK Associates Corp bought a new stake in Hims & Hers Health during the second quarter worth approximately $111,000. Finally, Amalgamated Bank increased its stake in Hims & Hers Health by 55.9% during the second quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock worth $133,000 after acquiring an additional 2,354 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets

HIMS has been the topic of several analyst reports. Needham & Company LLC initiated coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective on the stock. TD Cowen restated a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Piper Sandler restated a “neutral” rating and set a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft boosted their target price on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. Finally, Canaccord Genuity Group boosted their target price on Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $21.43.

Hims & Hers Health Stock Down 2.2 %

Hims & Hers Health stock opened at $30.19 on Thursday. The business has a fifty day moving average of $24.28 and a two-hundred day moving average of $20.80. The firm has a market cap of $6.60 billion, a P/E ratio of 68.61 and a beta of 1.25. Hims & Hers Health, Inc. has a twelve month low of $8.09 and a twelve month high of $35.02.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. The company had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Hims & Hers Health’s revenue was up 77.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.04) earnings per share. Equities analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total transaction of $38,593.50. Following the transaction, the insider now directly owns 176,952 shares of the company’s stock, valued at approximately $2,919,708. This represents a 1.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 33,513 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $33.38, for a total value of $1,118,663.94. Following the transaction, the chief executive officer now directly owns 33,502 shares in the company, valued at approximately $1,118,296.76. The trade was a 50.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 974,495 shares of company stock worth $22,548,139 over the last 90 days. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.